(Q53132270)

English

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.

scientific article published on 6 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

Efstathios Kastritis

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

Athanasios Dimopoulos

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

Evangelos Eleutherakis-Papaiakovou

5

object named as

E Eleutherakis-Papaiakovou

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

author name string

E Terpos

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

D Christoulas

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

M Gkotzamanidou

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

N Kanellias

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

A Papatheodorou

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

publication date

6 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

23

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

2681-2686

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

Expression and secretion of activin A: possible physiological and clinical implications

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

The regulation and functions of activin and follistatin in inflammation and immunity.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Changes in extracellular activin A:follistatin ratio during differentiation of a mesenchymal progenitor cell line, ROB-C26 into osteoblasts and adipocytes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Activin A is an essential cofactor for osteoclast induction.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

The activin A-follistatin system: potent regulator of human extracellular matrix mineralization

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Activin A and bone metastasis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Advances in imaging and the management of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Lenalidomide: an update on evidence from clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS068

21 January 2018

Identifiers

10.1093/ANNONC/MDS068

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22492699

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53132270&oldid=1744576349"